Product Images Oxaliplatin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Oxaliplatin NDC 0703-3986 by Teva Parenteral Medicines, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image 1
This text appears to be a medical treatment plan, including dosage instructions for various medications. It is suggested that a medical professional interprets and uses the information as necessary.*
image 2
image 3
This is a table of DFS probability data for two types of chemotherapy - FOLFOX4 and LVSFU2 - given to patients with arm numbers of 304/1123 and 360/1123, respectively. The table shows the hazard ratio, stratified logrank test, and number of patients at risk in each arm, as well as the number of events and percentage. The table also shows the DFS probability by month, with the number of patients at risk in each arm at each time point.*
image 4
This is a table for the probability of DFS (Disease-Free Survival) over different stages of chemotherapy for Dukes C cancer. It also shows the Hazard Ratio with a confidence interval of 95% and the Logrank Test results. Moreover, it shows the time intervals (in months) and the DFS values for treatment arms with FOLFOX4 and LV5FU2.*
image 5
This text provides survival data of different chemotherapy treatments for cancer patients. The percentage of patients surviving and the median survival months for three treatment options are presented. The treatment options include Oxaliplatin + FULV, Oxaliplatin + irinotecan, and Irinotecan + FULV. The statistic p<0.0001* is also provided.*
image 6
This is a drug with NDC code 0703-3985-01, called Reonly. It is an intravenous solution containing axaliplatin, lactose monohydrate, and water for injection. It is a sterile and preservative-free single-use vial that should be stored between 20° to 25°C (68° to 77°F). The drug requires dilution with 5% dextrose injection and should not be frozen. Its package insert contains dosage and administration information, and unused portions must be discarded. The drug is manufactured by TEVA PHARMACEUTICALS USA, INC., in Haarlem, The Netherlands. The quality of the text is good.*
image 7
The text describes a medication called "oxaliplatin", which is stored at a specific temperature range and is packaged in single-use vials. It is a sterile, preservative-free solution that must be diluted prior to intravenous use with dextrose injection. Each vial contains 100mg of oxaliplatin and lactose monohydrate. It includes warnings and instructions for use, and is manufactured by Teva Pharmaceuticals USA, Inc.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.